TRF-2 Upholds Ongoing Cancer Treatment Under Health Plan

This page is a translation of the original Portuguese text, provided for convenience. It deals with Brazilian law. If there is any discrepancy, the Portuguese version prevails. Read the original in Portuguese

The Federal Regional Court of the 2nd Region (TRF-2) has confirmed a preliminary injunction that guarantees, on a collective basis, continued treatment for cancer patients covered by a health plan operator in Rio de Janeiro. The order covers therapies, medications, and the hospital network that was previously accredited.

What the Panel Decided

The dispute reached TRF-2 through an interlocutory appeal (agravo de instrumento) filed in the course of a public civil action (ação civil pública, a type of collective lawsuit) brought in 2025. The organization that filed the suit reported a series of failures attributed to the operator, including the removal of health professionals and facilities from its network, as well as denials of coverage for procedures related to cancer treatment.

In reviewing the request, the panel ordered that plan members under oncology care continue to receive treatment on the same terms as before. This includes access to hospitals already under contract, continuation of ongoing therapies, and the supply of the medications required by each patient’s individualized treatment protocol.

The decision is a preliminary injunction. With its confirmation on appeal, however, it gains procedural stability and takes effect immediately for all the patients represented in the collective action. The measure reflects the principle of protecting continuity of care, which is considered vital in cancer cases because the disease is progressive and therapeutic interventions are highly time-sensitive.

Why Continuity of Care Matters

Cancer treatment requires meticulous planning, with a sequence of tests, chemotherapy sessions, radiation therapy, surgeries, and specific medications. Any abrupt interruption can undermine clinical effectiveness and increase the risk to the patient’s life. For that reason, decisions addressing coverage denials in this context tend to prioritize preserving the current course of treatment until the court makes a final ruling on the merits.

Brazilian courts have established the understanding that the relationship between a patient in cancer treatment and a health plan operator has special characteristics. The consumer’s vulnerability, combined with the ongoing nature of the disease, justifies a broad reading of contract clauses whenever a restrictive interpretation would put the member’s health at risk. Objective good faith (boa-fé objetiva) and the social function of the contract serve as central interpretive guides.

Abruptly interrupting a cancer treatment protocol can undermine clinical effectiveness and increase the risk to the patient’s life.

The removal of providers from a plan’s network also deserves attention. Changes to the provider network that affect services essential to a treatment already underway may amount to a breach of the member’s legitimate contractual expectations and violate the regulatory rules of the supplementary health sector. The geographic proximity of the service, the professional’s specialty, and the therapeutic relationship already established all factor into a court’s assessment of whether the change is reasonable.

Regulatory Framework Involved

The supplementary health care sector is governed by a specific federal statute that sets duties of disclosure, transparency, and minimum coverage. Brazil’s National Supplementary Health Agency issues additional regulations on the list of covered procedures, maximum waiting times for care, and rules on removing providers from a network. Case law, in turn, integrates this framework with the consumer protection microsystem, giving special weight to the patient’s vulnerability.

Effects on the Affected Members

Under the court’s decision, the cancer patients covered by the collective action are guaranteed that their treatment already underway will continue. In practice, this means the operator must keep existing appointments, make hospitalization available when it is indicated, authorize the next sessions of the protocol, and pay for the prescribed medications.

Members who encounter any administrative resistance after the decision can report the situation to the organization that filed the action or file a complaint with the regulatory agency. Documentation of the care received, including authorization forms, prescriptions, and medical reports, is essential to prove any noncompliance and to support individual requests to enforce the decision.

The organization that brought the action has already signaled its intention to broaden the scope of the decision. It mentioned the possibility of filing motions for clarification (embargos de declaração) to include neurodivergent patients who also depend on continued treatment within the scope of the injunction. This step illustrates the use of collective actions as a tool to protect vulnerable groups with similar therapeutic needs.

Best Practices for Patients in Treatment

When you face any difficulty accessing care, organized documentation and knowing the right channels for complaints make a difference. The following practical recommendations are often useful in situations involving health plans and cancer treatment:

1. Keep copies of all requests, authorizations, forms, and medical reports in chronological order;
2. Obtain a protocol number for each denial through the operator’s official channels, noting the date, time, and name of the representative;
3. Request in writing the grounds for any denial affecting urgent or ongoing procedures;
4. Tell your medical team about any barriers to access so the treatment plan can be adjusted;
5. Contact the regulatory agency or the public defender’s office in situations that put your health at risk;
6. Seek specialized legal advice to evaluate individual measures or joining collective relief currently in effect.

Outlook and Next Procedural Steps

The decision is a preliminary injunction, which means it will be revisited when the court rules on the merits of the public civil action. Until then, the protective effect for the represented patients remains in place. Appeals against the panel’s decision are possible, but whether they suspend its effects depends on review by a higher court, which will examine the requirements of risk and plausibility.

The outcome of the case may establish important parameters for the relationship between operators and members undergoing cancer treatment, especially regarding the removal of providers from a network and the continuity of treatment protocols. The impact is likely to influence similar claims in other courts, particularly in states where collective actions with the same subject matter are pending.

If you are a patient, the recommendation is to keep to your treatment schedule, promptly report any obstacle, and seek legal advice to evaluate the best strategy for your specific case. Each situation has its own particulars that deserve individual analysis, taking into account the stage of treatment, the type of procedure required, and the terms of the contract signed with the operator.

Frequently Asked Questions

Does the court’s decision cover all of the operator’s patients?

The decision was issued in a public civil action and covers the group of patients represented in the case, as defined by the court. Members in the same situation may rely on the collective decision through the appropriate procedural mechanisms, always with an individualized assessment of the circumstances of the contract and the treatment underway. Specialized legal advice can help determine whether it applies to your case.

What should you do if coverage for cancer treatment is denied?

The first step is to demand the denial in writing, stating the specific grounds the operator is relying on. Next, you should gather your medical documentation, file a complaint with the appropriate regulatory channels, and work with a qualified professional to evaluate the available court measures, such as requests for urgent injunctive relief (tutela de urgência). Speed is essential, especially when there is a risk that a treatment protocol already underway will be interrupted.

Is it permitted to remove a hospital or doctor from the network during treatment?

Removing a provider from a network is subject to strict regulatory rules, especially when it affects services essential to treatment already underway. The operator must observe deadlines, provide equivalent alternatives, and notify the member in advance. When a removal compromises the continuity of cancer care, the patient may challenge the change in court based on contractual good faith and the ancillary duties that arise from the consumer relationship.

As informações deste artigo são de caráter informativo e não substituem consulta jurídica individualizada. Cada caso possui particularidades que exigem análise específica.